All Pharma News
BlueRock phase I trial for Parkinson’s disease continues to show positive trends

BlueRock phase I trial for Parkinson’s disease continues to show positive trends
PRESS RELEASE
06 Mar 2024
Share Share
BlueRock exercises option to license iPSC cell therapy candidate OpCT-001

BlueRock exercises option to license iPSC cell therapy candidate OpCT-001
PR NEWSWIRE
23 Jan 2024
Share Share
BlueRock’s Phase I study with bemdaneprocel in patients meets primary endpoint

BlueRock’s Phase I study with bemdaneprocel in patients meets primary endpoint
PRESS RELEASE
02 Oct 2023
Share Share
BlueRock`s Ph I study with bemdaneprocel with PD meets primary endpoint

BlueRock`s Ph I study with bemdaneprocel with PD meets primary endpoint
PR NEWSWIRE
28 Aug 2023
Share Share
Bayer-owned BlueRock cuts 12% of staff as pipeline contracts

Bayer-owned BlueRock cuts 12% of staff as pipeline contracts
Max Bayer FIERCE BIOTECH
17 Aug 2023
Share Share
BlueRock Therapeutics & bit.bio announce collaboration for Treg based therapies

BlueRock Therapeutics & bit.bio announce collaboration for Treg based therapies
PR NEWSWIRE
03 Aug 2023
Share Share
Bayer: Phase I trial results from Parkinson`s cell therapy positive

Bayer: Phase I trial results from Parkinson`s cell therapy positive
REUTERS
28 Jun 2023
Share Share
Bayer`s BlueRock taps Rune Labs for Parkinson`s study software

Bayer`s BlueRock taps Rune Labs for Parkinson`s study software
Joseph Keenan FIERCE BIOTECH
16 Mar 2023
Share Share
BioCardia with BlueRock to Provide Catheter Biotherapeutic Delivery Candidates

BioCardia with BlueRock to Provide Catheter Biotherapeutic Delivery Candidates
GLOBENEWSWIRE
24 Aug 2022
Share Share
New Berlin site to accelerate cell therapy innovation for BlueRock Therapeutics

New Berlin site to accelerate cell therapy innovation for BlueRock Therapeutics
Sarah Wills EUROPEANPHARMACEUTICALREVIEW
14 Jun 2022
Share Share